Oppenheimer Holdings Inc (OPY) · Oct 30, 2026 · Earnings

Oppenheimer earnings miss as capital markets swing to loss

Miss — Basic EPS $0.52 vs $2.06 prior year

Oppenheimer’s Q3 earnings show record AUM strength, but weaker trading and investment banking pushed revenue down 10% and capital markets into a loss.

Oppenheimer entered this quarter as a two-engine middle-market financial firm: a steadily expanding wealth-management platform alongside a capital-markets business expected to benefit from stronger investment-banking activity. Recent company materials highlighted record client assets and a recovering investment-banking platform as key growth drivers.

The quarter was materially weaker than the standing growth story. Revenue fell 10.0% year over year to $382.0 million, while basic EPS dropped to $0.52 from $2.06. With no reliable published Q3 consensus available, the cleanest benchmark is the prior-year quarter—and on that basis this was a clear earnings miss.

3Q 20263Q 2025
Revenue (Consolidated Income Statements)$382.0M (-10.0%)$424.4M
Basic EPS (Consolidated Income Statements)$0.52 (-74.8%)$2.06
Adjusted basic EPS (Non-GAAP reconciliation)$1.96 (-34.9%)$3.01
Wealth Management revenue (Segment results)$266.2M (+2.5%)$259.7M
Wealth Management pre-tax income (Segment results)$55.6M (-11.0%)$62.5M
Capital Markets revenue (Segment results)$114.0M (-29.7%)$162.1M
Capital Markets pre-tax income (Segment results)($9.9M)$12.3M
AUM (Wealth Management results)$59.6B$55.1B

Wealth management is holding up operationally, but not converting growth into equal profit growth. Revenue increased 2.5% as advisory fees rose 15.3% and AUM reached a record $59.6 billion. But pre-tax income fell 11.0% because lower retail commissions, weaker sweep income, and higher technology and compensation costs offset the advisory-fee gains. The good news is asset gathering remains intact; the weaker point is that profitability softened despite that asset base.

Capital markets is the central setback. Revenue dropped 29.7% and the segment swung from $12.3 million of pre-tax income to a $9.9 million loss. Investment-banking revenue was especially weak: equity underwriting fell 82.0%, while fewer M&A transactions reduced advisory fees. Equities trading improved, but not enough to offset the collapse in underwriting and the decline in fixed-income trading.

The stock-linked compensation charge explains part of the EPS damage, not the operating deterioration. A $21.0 million pre-tax stock-appreciation-rights expense reduced reported earnings, and the company says its revised formula will take several years to fully reduce that burden. Even excluding that charge, adjusted EPS fell to $1.96 from $3.01, showing that the underlying quarter still weakened materially.

Bottom line: Record AUM keeps the wealth-management foundation constructive, but this filing exposes a sharper capital-markets slowdown and weaker profitability than the prior-year benchmark. The event meaningfully sets back the near-term earnings story rather than merely reflecting a one-off accounting charge.

Original filing on SEC EDGAR

More Oppenheimer Holdings Inc news

Oppenheimer earnings miss as capital markets swing to loss | OPY Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.